ATE444969T1 - Dimerisiertes peptid - Google Patents
Dimerisiertes peptidInfo
- Publication number
- ATE444969T1 ATE444969T1 AT04702444T AT04702444T ATE444969T1 AT E444969 T1 ATE444969 T1 AT E444969T1 AT 04702444 T AT04702444 T AT 04702444T AT 04702444 T AT04702444 T AT 04702444T AT E444969 T1 ATE444969 T1 AT E444969T1
- Authority
- AT
- Austria
- Prior art keywords
- peptide
- tumor antigen
- dimerized peptide
- antigen peptide
- dimerized
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 239000000539 dimer Substances 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003007122 | 2003-01-15 | ||
| PCT/JP2004/000254 WO2004063217A1 (ja) | 2003-01-15 | 2004-01-15 | 二量体化ペプチド |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE444969T1 true ATE444969T1 (de) | 2009-10-15 |
Family
ID=32709100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04702444T ATE444969T1 (de) | 2003-01-15 | 2004-01-15 | Dimerisiertes peptid |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20060217297A1 (de) |
| EP (2) | EP1584627B1 (de) |
| JP (2) | JP4498274B2 (de) |
| KR (2) | KR101399678B1 (de) |
| CN (2) | CN101851275A (de) |
| AT (1) | ATE444969T1 (de) |
| AU (1) | AU2004204031B2 (de) |
| BR (1) | BRPI0406800B8 (de) |
| CA (1) | CA2513701C (de) |
| DE (1) | DE602004023476D1 (de) |
| ES (1) | ES2332590T3 (de) |
| WO (1) | WO2004063217A1 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1038929B (zh) * | 1998-07-31 | 2005-05-06 | 株式会社国际癌症免疫研究所 | 基於癌抑制基因wt1的产物的癌抗原 |
| EP1371664B1 (de) * | 2001-03-22 | 2008-01-09 | International Institute of Cancer Immunology, Inc. | Wti-modifiziertes peptid |
| US8021658B2 (en) * | 2001-05-25 | 2011-09-20 | Thomas Jefferson University | Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| AU2003262094A1 (en) * | 2002-09-12 | 2004-04-30 | Haruo Sugiyama | Cancer antigen peptide preparation |
| US20080070835A1 (en) | 2003-11-05 | 2008-03-20 | International Institute Of Cancer Immunology, Inc | Hla-Dr-Binding Antigen Peptide Derived From Wt1 |
| JP4886507B2 (ja) * | 2004-03-31 | 2012-02-29 | 株式会社癌免疫研究所 | Ｗｔ１由来の癌抗原ペプチド |
| JP2008528643A (ja) * | 2005-02-04 | 2008-07-31 | スルバック アーぺーエス | サバイビンペプチドワクチン |
| ES2352855T3 (es) * | 2005-11-30 | 2011-02-23 | International Institute Of Cancer Immunology, Inc. | Nuevos compuestos peptídicos del tumor de wilms. |
| CN102250211A (zh) | 2006-02-22 | 2011-11-23 | 株式会社癌免疫研究所 | Hla-a*3303限制性wt1肽和包含此肽的药物组合物 |
| PL1987063T3 (pl) * | 2006-02-23 | 2010-03-31 | Fibrex Medical Res & Development Gmbh | Peptydy i pochodne peptydów, ich wytwarzanie oraz ich zastosowanie do wytwarzania terapeutycznie i/lub profilaktycznie czynnej kompozycji farmaceutycznej |
| CA2886621A1 (en) | 2006-12-28 | 2008-07-10 | International Institute Of Cancer Immunology, Inc. | Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same |
| PL2119778T3 (pl) | 2007-02-27 | 2016-04-29 | Int Inst Cancer Immunology Inc | Sposób aktywacji pomocniczej komórki T oraz kompozycja do zastosowania w tym sposobie |
| ES2534434T3 (es) * | 2007-08-30 | 2015-04-22 | Curedm Group Holdings, Llc | Composiciones y métodos de uso de péptidos proislotes y análogos de los mismos |
| NZ609460A (en) | 2010-10-05 | 2015-07-31 | Otsuka Pharma Co Ltd | Method for activating helper t cell |
| CN103282375B (zh) * | 2010-12-02 | 2017-01-11 | 比奥诺尔免疫有限公司 | 肽支架设计 |
| KR20130133212A (ko) * | 2010-12-23 | 2013-12-06 | 인터셀 오스트리아 아게 | 입원 및 다른 환자에서 OprF/I 물질 및 이의 용도 |
| AU2012204955B2 (en) | 2011-01-06 | 2016-10-06 | Bionor Immuno As | Monomeric and multimeric immunogenic peptides |
| WO2012105224A1 (ja) * | 2011-01-31 | 2012-08-09 | オリンパス株式会社 | ワクチン・アジュバント |
| ES2655031T3 (es) | 2012-07-02 | 2018-02-16 | Sumitomo Dainippon Pharma Co., Ltd. | Preparación transdérmica de péptido antigénico del cáncer |
| EA201591168A1 (ru) | 2012-12-17 | 2016-05-31 | Оцука Фармасьютикал Ко., Лтд. | Способ активации хелперной t-клетки |
| JP6294868B2 (ja) | 2013-03-12 | 2018-03-14 | 大日本住友製薬株式会社 | 液体水性組成物 |
| EP2982681B8 (de) * | 2013-03-29 | 2018-11-07 | Sumitomo Dainippon Pharma Co., Ltd. | Wt1-antigen-peptid-konjugat-vakzin |
| EP2980097A4 (de) * | 2013-03-29 | 2017-03-08 | Sumitomo Dainippon Pharma Co., Ltd. | Konjugatimpfstoff mit trimmfunktion von erap1 |
| KR20160063349A (ko) | 2013-10-17 | 2016-06-03 | 서울대학교산학협력단 | 알파나선형 세포 투과 펩타이드 다합체，이의 제조방법 및 그 용도 |
| ES2916834T3 (es) * | 2014-09-27 | 2022-07-06 | Sumitomo Pharma Co Ltd | Composición farmacéutica para inyección |
| JP6671141B2 (ja) * | 2014-10-21 | 2020-03-25 | 大日本住友製薬株式会社 | 懸濁液剤 |
| US20180140691A1 (en) * | 2015-05-20 | 2018-05-24 | Sumitomo Dainippon Pharma Co., Ltd. | Combination use of wt1 antigen peptide and immunomodulator |
| CA2992419C (en) | 2015-07-14 | 2023-08-15 | Yeda Research And Development Co. Ltd. | Peptide combinations for use in the diagnosis of schizophrenia |
| US12383608B2 (en) | 2016-11-30 | 2025-08-12 | Sumitomo Pharma Co., Ltd. | WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides |
| JPWO2019131722A1 (ja) * | 2017-12-27 | 2021-01-14 | 大日本住友製薬株式会社 | Ｗｔ１由来ペプチドのコンジュゲート体およびこれを含む組成物 |
| US12233130B2 (en) * | 2022-12-22 | 2025-02-25 | Defence Therapeutics Inc. | Covalently-modified steroid acid-peptides having enhanced stability and/or biological activity |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2268705T3 (es) * | 1995-06-01 | 2007-03-16 | Kishimoto, Tadamitsu | Inhibidor del crecimiento de celulas leucemicas que contienen un derivado oligonucleotidico antisentido frente al gen del tumor de wiloms (wt1). |
| JP3060287B2 (ja) | 1995-10-09 | 2000-07-10 | 参天製薬株式会社 | アパファントを主薬とする水性点眼剤 |
| HK1038929B (zh) * | 1998-07-31 | 2005-05-06 | 株式会社国际癌症免疫研究所 | 基於癌抑制基因wt1的产物的癌抗原 |
| US7063854B1 (en) * | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
| PL201881B1 (pl) | 1998-09-30 | 2009-05-29 | Corixa Corp | Izolowany polipeptyd składający się z immunogennej części natywnego WT1, zawierająca go kompozycja farmaceutyczna i szczepionka oraz polinukleotyd kodujący ten polipeptyd |
| GB9823897D0 (en) * | 1998-11-02 | 1998-12-30 | Imp College Innovations Ltd | Immunotherapeutic methods and molecules |
| AU2002222610A1 (en) | 2000-12-13 | 2002-06-24 | Sumitomo Pharmaceuticals Company, Limited | Transgenic animal expressing hla-a24 and utilization thereof |
| EP1371664B1 (de) | 2001-03-22 | 2008-01-09 | International Institute of Cancer Immunology, Inc. | Wti-modifiziertes peptid |
| US8735357B2 (en) * | 2001-09-28 | 2014-05-27 | International Institute Of Cancer Immunology, Inc. | Method of inducing antigen-specific T cells |
| US20050002951A1 (en) * | 2001-09-28 | 2005-01-06 | Haruo Sugiyama | Novel method of inducing antigen-specific t cells |
| WO2003106682A1 (ja) * | 2002-06-12 | 2003-12-24 | 中外製薬株式会社 | Ｈｌａ−ａ２４拘束性癌抗原ペプチド |
| US20080070835A1 (en) | 2003-11-05 | 2008-03-20 | International Institute Of Cancer Immunology, Inc | Hla-Dr-Binding Antigen Peptide Derived From Wt1 |
| JP4886507B2 (ja) | 2004-03-31 | 2012-02-29 | 株式会社癌免疫研究所 | Ｗｔ１由来の癌抗原ペプチド |
-
2004
- 2004-01-15 KR KR1020057012761A patent/KR101399678B1/ko not_active Expired - Lifetime
- 2004-01-15 AT AT04702444T patent/ATE444969T1/de not_active IP Right Cessation
- 2004-01-15 DE DE602004023476T patent/DE602004023476D1/de not_active Expired - Lifetime
- 2004-01-15 EP EP04702444A patent/EP1584627B1/de not_active Expired - Lifetime
- 2004-01-15 EP EP09172205.8A patent/EP2154145B1/de not_active Expired - Lifetime
- 2004-01-15 KR KR1020127008760A patent/KR20120054644A/ko not_active Withdrawn
- 2004-01-15 CN CN201010156098A patent/CN101851275A/zh active Pending
- 2004-01-15 US US10/541,821 patent/US20060217297A1/en not_active Abandoned
- 2004-01-15 CN CN2004800058473A patent/CN1756763B/zh not_active Expired - Lifetime
- 2004-01-15 ES ES04702444T patent/ES2332590T3/es not_active Expired - Lifetime
- 2004-01-15 JP JP2005508011A patent/JP4498274B2/ja not_active Expired - Lifetime
- 2004-01-15 CA CA2513701A patent/CA2513701C/en not_active Expired - Lifetime
- 2004-01-15 BR BRPI0406800A patent/BRPI0406800B8/pt not_active IP Right Cessation
- 2004-01-15 WO PCT/JP2004/000254 patent/WO2004063217A1/ja not_active Ceased
- 2004-01-15 AU AU2004204031A patent/AU2004204031B2/en not_active Expired
-
2009
- 2009-11-16 JP JP2009260957A patent/JP4926231B2/ja not_active Expired - Lifetime
-
2010
- 2010-06-07 US US12/795,187 patent/US8242084B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2154145A2 (de) | 2010-02-17 |
| CA2513701A1 (en) | 2004-07-29 |
| DE602004023476D1 (de) | 2009-11-19 |
| HK1081975A1 (en) | 2006-05-26 |
| BRPI0406800A8 (pt) | 2016-11-01 |
| EP2154145A3 (de) | 2010-05-19 |
| US20060217297A1 (en) | 2006-09-28 |
| EP2154145B1 (de) | 2013-04-24 |
| BRPI0406800B1 (pt) | 2020-08-11 |
| AU2004204031A1 (en) | 2004-07-29 |
| AU2004204031B2 (en) | 2010-03-04 |
| CN1756763B (zh) | 2010-05-26 |
| KR101399678B1 (ko) | 2014-05-27 |
| EP1584627B1 (de) | 2009-10-07 |
| JPWO2004063217A1 (ja) | 2006-06-01 |
| BRPI0406800A (pt) | 2006-01-17 |
| CN1756763A (zh) | 2006-04-05 |
| HK1141539A1 (en) | 2010-11-12 |
| US8242084B2 (en) | 2012-08-14 |
| ES2332590T3 (es) | 2010-02-09 |
| WO2004063217A1 (ja) | 2004-07-29 |
| CA2513701C (en) | 2013-06-18 |
| JP2010047603A (ja) | 2010-03-04 |
| JP4498274B2 (ja) | 2010-07-07 |
| BRPI0406800B8 (pt) | 2021-05-25 |
| EP1584627A4 (de) | 2006-03-15 |
| US20100292164A1 (en) | 2010-11-18 |
| KR20050098863A (ko) | 2005-10-12 |
| CN101851275A (zh) | 2010-10-06 |
| KR20120054644A (ko) | 2012-05-30 |
| JP4926231B2 (ja) | 2012-05-09 |
| EP1584627A1 (de) | 2005-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004023476D1 (de) | Dimerisiertes peptid | |
| CY1118037T1 (el) | Αντισωματα εναντι του αβητα και h χρηση τους | |
| WO2007064919A3 (en) | Binding polypeptides with restricted diversity sequences | |
| CY1119106T1 (el) | Αντισωματα εναντι masp-2 | |
| ATE415413T1 (de) | Iap-bindende verbindungen | |
| CY1113850T1 (el) | Νεα παραγωγα ινσουλινης | |
| NO20075927L (no) | IL-21 varianter | |
| WO2005012531A3 (en) | Antibody cdr polypeptide sequences with restricted diversity | |
| CY1117031T1 (el) | Μονοκλωνικα αντισωματα εναντι claudin-18 στην αγωγη εναντι καρκινου | |
| DK1423419T3 (da) | Hybrid- og tandemekspression af Neisseria-proteiner | |
| CY1108960T1 (el) | Αντισωματα αποκλεισμου cripto και οι χρησεις τους | |
| ATE545703T1 (de) | Multivalentes zielbindendes protein | |
| DE60232577D1 (de) | Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential | |
| ATE542137T1 (de) | Immunocytokine mit modulierter selektivität | |
| DE602005008996D1 (de) | Radiofluorierte peptide | |
| CY1106662T1 (el) | Αντι-igf-ir αντισωματα και οι εφαρμογες τους | |
| DE502004011395D1 (de) | Protein-bindende doxorubicin-peptid-derivate | |
| PE20050962A1 (es) | Anticuerpos completamente humanos contra 4-1bb humano | |
| EP2305710A3 (de) | Synthetische Antikörperphagenbibliotheken | |
| EA200600042A1 (ru) | Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах | |
| ATE419861T1 (de) | Peptide mit homing für lymphgefässtumor und ihre verwendung | |
| ATE467421T1 (de) | Cytokine und cytokinrezeptoren mit reduzierter immunogenität | |
| ATE470678T1 (de) | Emitter-bindende peptide, die eine veränderung der spektralen emissionseigenschaften des emitters bewirken | |
| ATE404581T1 (de) | Faserformgebende peptide, die mit selbstanordnenden peptiden interagieren | |
| CY1117092T1 (el) | Μοτιβα της οικογενειας παγκρεατικων πολυπεπτιδιων, πολυπεπτιδια και μεθοδοι που τα περιλαμβανουν |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |